```html

Fibrillary Glomerulonephritis (FGN) – A Patient‑Focused Guide

Overview

Fibrillary glomerulonephritis (FGN) is a rare, primary kidney disease characterized by the deposition of randomly arranged, non‑branching fibrils (≈20 nm in diameter) within the glomerular basement membrane and mesangium. These fibrils are composed of polyclonal immunoglobulin G (IgG) and complement components, leading to inflammation and scarring of the filtering units of the kidney.

• Who it affects: Adults, most commonly between 40 and 70 years of age. Slight male predominance (≈55 % men).
• Prevalence: FGN accounts for <1 % of all primary glomerular diseases and roughly 0.5–1 % of native kidney biopsies in tertiary centers.<sup>1</sup>

Because the disease is uncommon and symptoms often mimic other kidney disorders, a definitive diagnosis usually requires a kidney biopsy examined by electron microscopy.

Symptoms

FGN may be discovered incidentally on routine labs, or it may present with progressive kidney dysfunction. The clinical picture can vary, but the most frequent manifestations include:

1. Proteinuria

• Often in the nephrotic range (≥3.5 g/24 h) in 30–40 % of patients.
• May be accompanied by frothy urine.

2. Edema

• Swelling of the ankles, feet, or periorbital area due to fluid retention.

3. Hematuria

• Microscopic (most common) or occasional gross (visible) blood in urine.

4. Hypertension

• Elevated blood pressure in about half of patients, often resistant to standard therapy.

5. Declining Kidney Function

• Rising serum creatinine and reduced estimated glomerular filtration rate (eGFR); average decline of 10–15 mL/min/1.73 m² per year in untreated patients.<sup>2</sup>

6. Systemic Symptoms (less common)

• Fatigue, loss of appetite, and unintentional weight loss.
• Rarely, associated with underlying lymphoproliferative disorders (e.g., chronic lymphocytic leukemia).

Causes and Risk Factors

The exact trigger for fibrillary deposition remains unknown, but research points to several potential contributors:

1. Primary (Idiopathic) Disease

• In ~70 % of cases, no underlying systemic disease is identified.

2. Secondary Associations

• Lymphoproliferative disorders: Chronic lymphocytic leukemia, lymphoma, or multiple myeloma in 5–10 % of patients.<sup>3</sup>
• Autoimmune conditions: Systemic lupus erythematosus and rheumatoid arthritis (rare).
• Infections: Hepatitis C and HIV have been reported in isolated cases.

3. Demographic Risk Factors

• Age >40 years.
• Male sex (modest increase).
• African‑American ethnicity appears slightly over‑represented, though data are limited.

4. Genetic/Immunologic Factors

• Polyclonal IgG deposition suggests an abnormal immune response; specific HLA alleles have not been definitively linked.

Diagnosis

Because clinical features overlap with many other kidney diseases, diagnosis hinges on kidney tissue analysis.

1. Laboratory Evaluation

• Urine studies: Protein quantification (24‑hour collection or spot protein/creatinine ratio), microscopy for hematuria.
• Blood tests: Serum creatinine, eGFR, albumin, complement levels (C3, C4), and serologies for hepatitis, HIV, and autoimmune markers.

2. Imaging

• Renal ultrasound to assess kidney size and rule out obstruction; usually normal in early FGN.

3. Kidney Biopsy – The Cornerstone

1. Light microscopy: Shows mesangial expansion, capillary wall thickening, and often a “lobular” pattern.
2. Immunofluorescence (IF): Diffuse, granular IgG (often IgG4) and C3 staining, occasionally with kappa and lambda light chains.
3. Electron microscopy (EM): Reveals randomly arranged, non‑branching fibrils measuring 18–24 nm—distinct from the 10 nm fibrils of amyloidosis.

When EM is not available, a “negative Congo red” stain (ruling out amyloid) combined with characteristic IF patterns can raise suspicion, but definitive diagnosis still requires EM.

4. Exclusion of Secondary Causes

Comprehensive work‑up for malignancy, chronic infections, and systemic autoimmune disease is recommended to identify treatable underlying conditions.

Treatment Options

There is no universally accepted therapy, and management is individualized based on disease severity, proteinuria level, and presence of an associated condition.

1. Immunosuppressive Regimens

• Corticosteroids: Prednisone 0.5–1 mg/kg/day tapered over 6–12 months; often combined with another agent.
• Rituximab (anti‑CD20 monoclonal antibody): 375 mg/m² weekly for 4 weeks or 1 g on days 1 and 15; retrospective series show proteinuria reduction in ~40 % of patients.<sup>4</sup>
• Cyclophosphamide or Mycophenolate Mofetil (MMF): Used as steroid‑sparing agents; evidence is limited to case series.
• Proteasome inhibitors (e.g., bortezomib): Investigational for patients with associated plasma‑cell dyscrasias.

2. Supportive Kidney Care

• Renin‑angiotensin‑aldosterone system (RAAS) blockade: ACE inhibitors or ARBs to reduce proteinuria and control blood pressure.
• Diuretics: For volume overload and edema.
• Statins: If dyslipidemia is present (common in nephrotic‑range proteinuria).

3. Management of Underlying Conditions

• Treating an associated lymphoma, hepatitis C, or autoimmune disease can improve renal outcomes.

4. Renal Replacement Therapy

• Approximately 30–40 % of patients progress to end‑stage kidney disease (ESKD) within 5 years.<sup>5</sup>
• Hemodialysis, peritoneal dialysis, or kidney transplantation may become necessary.
• Recurrence after transplantation occurs in ~30 % of cases; rituximab prophylaxis is sometimes employed.

5. Clinical Trials

Patients should be encouraged to enroll in trials investigating novel agents (e.g., complement inhibitors, B‑cell targeting therapies) because evidence is evolving.

Living with Fibrillary Glomerulonephritis

While the disease can be challenging, many patients maintain a good quality of life with proper management.

1. Medication Adherence

• Take immunosuppressants exactly as prescribed; missed doses can trigger flare‑ups.
• Monitor for side effects—watch for infections, glucose intolerance, or bone loss.

2. Blood Pressure & Proteinuria Control

• Target BP < 130/80 mmHg (or individualized goal per your nephrologist).
• Regular urine protein checks (every 3–6 months).

3. Lifestyle Strategies

• Diet: Low‑salt (≤2 g sodium/day), moderate protein (0.8 g/kg/day), and heart‑healthy fats.
• Fluid balance: Follow your doctor's guidance—some need fluid restriction if edema is severe.
• Exercise: Aim for 150 minutes of moderate activity weekly, unless contraindicated.
• Vaccinations: Stay up‑to‑date with influenza, pneumococcal, hepatitis B, and COVID‑19 vaccines (immunosuppressed patients are at higher infection risk).

4. Monitoring Schedule

Visit	Tests
Every 3 months (first year)	Serum creatinine/eGFR, urine protein, BP, medication side‑effects
Every 6–12 months thereafter	Renal panel, lipid profile, CBC, vaccination status

5. Emotional & Social Support

• Connect with patient advocacy groups (e.g., National Kidney Foundation).
• Consider counseling to cope with chronic disease stress.

Prevention

Because most cases are idiopathic, primary prevention is limited. However, risk reduction strategies focus on maintaining overall kidney health and early detection of associated conditions.

• Control hypertension and diabetes—leading causes of secondary kidney injury.
• Avoid nephrotoxic agents (e.g., NSAIDs, certain antibiotics) unless medically necessary.
• Screen for and treat underlying hematologic or infectious disorders promptly.
• Stay current with vaccinations to reduce infection‑related immune activation.

Complications

If untreated or poorly controlled, FGN can lead to serious outcomes:

• End‑Stage Kidney Disease (ESKD): Need for dialysis or transplant.
• Thromboembolic events: Nephrotic syndrome increases clot risk (deep vein thrombosis, pulmonary embolism).
• Infections: Immunosuppression heightens susceptibility to bacterial, viral, and fungal infections.
• Hypertensive emergencies: Uncontrolled BP can cause cerebrovascular accidents or cardiac injury.
• Medication toxicity: Chronic steroid use may cause osteoporosis, cataracts, and glucose intolerance.

When to Seek Emergency Care

---

**References**

1. Nasr SH, et al. Fibrillary glomerulonephritis. Nat Rev Nephrol. 2019.
2. Centers for Disease Control and Prevention (CDC). Kidney disease statistics.
3. Mayo Clinic. Glomerulonephritis overview.
4. Cleveland Clinic. Treatment of FGN.
5. National Institutes of Health (NIH). Kidney disease progression data.

```